Recent Finacing
Recent Raise
Renexxion Ireland is a Roscrea‑based biopharmaceutical developing minimally absorbable, gut‑lumen active naronapride (5‑HT4 agonist/D2 antagonist) for CIC and GERD (Phase III ready), plus IBD programs, partnering for European/Australasian commercialization.
